Choongwe: New quinolone compound Q-35 on clinical phase III

Published: 1999-04-27 18:40:00

Updated: 1999-04-27 18:40:00

A new quinolone antibacterial drug, Q35 (Curoxin) will be performed its phase III clinical study accorded to the ICH standards at 13 hospitals including SNU hospital, starting from April, said Choongwe on April 22.

Choongwe obtained the approval for the phase III clinical study from the KFDA a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK